AKTX Stock Analysis: Buy, Sell, or Hold?
AKTX - Akari Therapeutics plc ADR (0.01 USD)
$5.15
5.03 (4156.20%)
▲
5d:
+3645.45%
30d:
+2085.91%
90d:
+1869.41%
WAIT
LOW Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: Apr 15, 2026
13d
Get Alerted When AKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: AKTX is 296.2% above fair value ($1.30). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: AKTX is 296.2% above fair value ($1.30). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: AKTX is currently trading at $5.15, which is considered extended relative to its 30-day fair value range of $-0.53 to $1.30.
Technical Outlook: Technically, AKTX is showing sideways momentum. Immediate support is located at $0.12, while resistance sits at $5.45. The stock is showing strong short-term momentum, up 4156.2% recently.
Market Sentiment: AKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $4.53. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKTX is showing sideways momentum. Immediate support is located at $0.12, while resistance sits at $5.45. The stock is showing strong short-term momentum, up 4156.2% recently.
Market Sentiment: AKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $4.53. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$-0.53 -
$1.30
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+296.2% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4156.2%)
- BEARISH: Trading 12.0% above Wall St target ($4.53)
- WARNING: Recommendation downgraded due to 296.2% overvaluation
Fair Price Analysis
30-Day Fair Range
$-0.53 -
$1.30
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$0.12
Resistance Level
$5.45
Current Trend
Sideways
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.88
Wall Street Target
$4.53
(-12.0%)
Share & Embed Analysis
Last updated: March 31, 2026 8:23 PM ET
Data refreshes hourly during market hours. Next update: 9:23 PM
Data refreshes hourly during market hours. Next update: 9:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 65 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 43 HOLD |
